Biotechnology markets for bioprocess analyzers and biobanking projected to grow

The bioprocess analyzers and biobanking markets are projected to see significant growth driven by advancements in biotechnology and the expansion of cell and gene therapies.

The bioprocess analyzers market, valued at USD 2.42 billion in 2025, is expected to reach USD 7.71 billion by 2035. This growth is fueled by increased production of biologics, such as monoclonal antibodies, vaccines, and recombinant proteins, alongside the rising use of real-time monitoring and Process Analytical Technology (PAT). North America currently holds the largest regional market share, while the Asia Pacific region is identified as the fastest-growing.

Simultaneously, the biobanking market is forecasted to grow from USD 8.09 billion in 2026 to USD 12.38 billion by 2031. Key drivers include the integration of artificial intelligence, automation, and digital technologies in sample management. The demand for specialized infrastructure to collect and preserve high-quality biological samples is rising as therapeutic manufacturing pipelines for cell and gene therapies continue to expand.